To illustrate the importance of identifying and classifying BRAF variants and guide precise treatment for patients with ICC based on our drug screens in patient-derived organoids, we evaluated 3 patients with advanced-stage ICC harboring endogenous BRAF variants whose tumor organoids we had tested for drug response (Figure 4). The gene discussed is BRAF; the disease is neoplasm.